BioMarin (BMRN) misses Q1 estimates as manufacturing, Amicus deal costs pressure margins

BioMarin Pharmaceutical (BMRN) reported first-quarter revenue growth but missed Wall Street’s revenue and non-GAAP profit expectations, as higher manufacturing-related costs and expenses tied to the Amicus acquisition weighed on margins. CFO Brian Mueller said profitability was “significantly impacted” by order timing, cost-of-sales charges and pre-close acquisition costs, which together reduced earnings by $0.20 per share. Management said demand remained strong for enzyme therapies and Voxzogo, with additional support from newly approved uses such as adolescent Palynziq. Investors are watching the integration of Amicus assets, including Galafold and Pombility/Opfolda, as well as upcoming clinical data for Voxzogo in hypochondroplasia and BMN-401 in ENPP1 deficiency. BioMarin shares recently traded at $54.95, little changed from $55.46 before the earnings update.